Skip to main content
Terug
LBRX logo

LB Pharmaceuticals Inc Common Stock

Datakwaliteit: 100%
LBRX
NASDAQ Healthcare Biotechnology
€ 23,67
▲ € 0,14 (0,60%)
Marktkapitalisatie: 598,83M
Dagbereik
€ 23,48 € 24,47
52-Weeksbereik
€ 13,36 € 27,55
Volume
113.426
50D / 200D Gem.
€ 23,15 / € 19,54
Vorige Slotkoers
€ 23,53

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -9,5 0,4
P/B 2,9
ROE % 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,2

Koersdoel Analisten

Hold
€ 33,33 +40.8%
Low: € 31,00 High: € 35,00
Forward WPA
-€ 4,05
Omzet Sch.
0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 -€ 4,59
-€ 6,12 – -€ 3,05
0 2
FY2027 -€ 3,89
-€ 4,68 – -€ 3,10
0 2
FY2026 -€ 4,05
-€ 5,08 – -€ 3,25
0 3

Belangrijkste Punten

Negative free cash flow of -53,82M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,56
Interest Coverage0,00

Waardering

P/E Ratio
-9,49
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -63,10M
ROE N/A ROA -188,17%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -53,82M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,56
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -9,49 P/B Ratio N/A
P/S Ratio N/A PEG Ratio 0,00
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 598,83M Enterprise Value 579,55M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 0,0 0,0 0,0
Net Income -63,10M -6,28M -14,35M
EPS (Diluted) -17,83 -1,77 -4,05
Gross Profit 0,0 0,0 0,0
Operating Income -64,83M -11,38M -2,81M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 33,53M 45,66M 21,49M
Total Liabilities 128,09M 80,13M 50,30M
Shareholders' Equity -94,55M -34,47M -28,81M
Total Debt 3,70M 0,0 24,15M
Cash & Equivalents 22,98M 14,98M 21,40M
Current Assets 28,88M 45,63M 21,49M
Current Liabilities 8,11M 2,61M 469.000,0